Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Lebanon Substitution Drug List

 
According to the Law No. 91 issued on 2010 related to the Pharmacist substitution right, the Ministry of Public Health conceived the Substitution Drug list. It is presented as a scientific, objective, reliable, accurate and accessible listing. This list is a helpful tool for Pharmacists and Health professionals and an information tool for patients as well.

The Substitution Drug List was compiled by a team of Pharmacists and Physicians from the Ministry of Public Health. It was inspired by the French Repertory of Generic Groups and the Lebanese National Drug Index (LNDI) which is the reference Guide for medicines in Lebanon.

The substitution could be done between an innovator product and a generic, based on the Ministry of Public Health Substitution list, providing that the product delivered is cheaper and has obtained the patient’s consent.

This Substitution Drug List, lists drugs, dosage forms, package sizes, drug strengths and other information registered at the Ministry of Public Health. It is divided into sections based on the Anatomical Therapeutic Chemical (ATC) classification system. The Innovator product is listed before the Generic products.

Information is shown in a convenient format with trade information in italics:
 
  ATCcode          
  Trade Name & Strength   B=Brand
G=Generic
 
  Route Form Container Presentation Code MOPH Registration Number at MOPH
    Active Ingredients with their respective dosage    
    Agent importing product Manufacturer Country of Origin  
        Responsible Party Country of Responsible Party
Each medication listing contains the following information:
  • ATC classification and code.
  • Trade name and strength of the formulation as registered at the Ministry of Public Health (MOH)
  • Generic (G) or Brand product (B)
  • Composition of the marketed form with the corresponding dosage of each active ingredient.
  • Form &presentation.
  • The local importer (agent), manufacturer and identified country of origin.
  • The Responsible Party and identified country.
  • The Ministry of Public Health database serial number (Code MOH) and legal registration document number (MOH reg)
 
The Substitution Drug List can be accessed from the official website of the Ministry of Public Health: www.moph.gov.lb

The Substitution Drug List welcomes comments from healthcare professionals. Please send comments to: [email protected]
 
 
Lebanon Substitution Drug List - First Edition 2015 (Revised)
    5
ATC Name B/G Ingredients Dosage Form Price
L01DC01 BLEO-CELL G Bleomycin (sulfate) - 15mg 15mg Injectable powder for solution 3,817,857 L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated 35,663,747 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated 123,564,667 L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated 154,453,246 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated L.L
L01EC03 BRAFTOVI BioTech Encorafenib - 50mg 50mg Capsule, hard 70,084,833 L.L
L01EC03 BRAFTOVI BioTech Encorafenib - 75mg 75mg Capsule, hard 149,227,143 L.L
L01FB01 BESPONSA FOR INJECTION BioTech Inotuzumab Ozogamicin - 0.9mg 0.9mg Injectable powder for suspension 921,176,511 L.L
L01FB01 BESPONSA FOR INJECTION BioTech Inotuzumab Ozogamicin - 0.9mg 0.9mg Injectable powder for suspension L.L
L01FF04 BAVENCIO BioTech Avelumab - 200mg/10ml 200mg/10ml Injectable concentrate for solution L.L
L01FF04 BAVENCIO BioTech Avelumab - 200mg/10ml 200mg/10ml Injectable concentrate for solution 104,075,577 L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable solution L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable solution L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable solution 49,744,595 L.L
L01FG01 BIVASTINA 400 BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 92,353,609 L.L
L01FG01 BIVASTINA 400 BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 53,111,763 L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable solution 14,719,570 L.L
L01FG01 BIVASTINA 100 BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 22,840,337 L.L
L01FG01 BIVASTINA 100 BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 12,021,318 L.L
L01FX07 BLINCYTO BioTech Blinatumomab - 35mcg 35mcg Injectable lyophilised powder for solution+stabilizer 239,484,334 L.L
L01FX07 BLINCYTO BioTech Blinatumomab - 35mcg 35mcg Injectable lyophilised powder for solution+stabilizer L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution L.L
L01XG01 BORCADE G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 11,020,381 L.L
L01XG01 BORCADE G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 11,020,381 L.L
L01XG01 BORTEZOMIB ACCORD G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 13,007,658 L.L
L01XG01 BORTEZOMIB GP PHARM G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 13,007,658 L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution 14,169,600 L.L
L01XG01 BORTEZOMIB SHILPA G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 9,902,420 L.L
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2025